By: IPP Bureau
Last updated : April 24, 2026 1:51 pm
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Gujarat Themis Biosyn Limited (GTBL) has announced the signing of an asset purchase agreement to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French multinational headquartered in Paris.
The proposed acquisition, which is subject to antitrust and foreign direct investment approvals in relevant jurisdictions, includes 13 established branded generic products with a presence in over 55 countries across Europe, the Middle East, and Africa. The portfolio reported net sales of approximately EUR 62 million for the year ended 2025.
As part of the transaction, Gujarat Themis Biosyn will acquire marketing authorisations, brands, regulatory dossiers, inventory, and associated commercial rights. The deal does not include transfer of manufacturing facilities or employees, making it a capital-efficient and asset-light expansion for the company.
The total consideration for the transaction is EUR 158 million, payable in cash at closing, and is expected to be funded through an optimal mix of debt and equity. The deal is expected to be EPS accretive, supported by branded generics sales, vertical integration, and improved operating leverage.
The company said the acquisition marks a significant step in its strategy to strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment. It is expected to provide immediate access to regulated and semi-regulated markets, enabling a stronger international footprint.
GTBL also highlighted potential forward integration benefits, leveraging its existing fermentation-based intermediates and API capabilities to support the finished dosage formulations portfolio, thereby improving value-chain realisations.
Dr Sachin Patel, Managing Director, GTBL, said: “This move would serve as a gateway to extend our patient reach, explore and penetrate new regulated territories, establishing a truly global footprint for our specialized offerings. Controlling the process from fermentation to the final product minimizes supply chain risks and ensures long-term profitability improvement. With multiple levers for value creation under our direct control, this acquisition will position GTBL to deliver consistent, long-term shareholder value while reinforcing our leadership in the fermentation space and growing the impact we have in global healthcare.”